deslorelin

Ovuplant is tradename for a short-term-release implant containing deslorelin acetate; RN given refers to D-isomer; RN for cpd without isomeric designation not avail 12/90

Also Known As:

6-Trp-10-N-Et-GlyNH2-LHRH; D-Trp(6)-N-Et-D-GlyNH2(10)-LHRH; GnRh, Trp(6)-N-Et-GlyNH2(10)-; LHRH, Trp(6)-N-Et-GlyNH2(10)-; LHRH, tryptophyl(6)-N-ethylglycinamide(10)-; Ovuplant; Somagard; deslorelin acetate

Networked: 55 relevant articles (6 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kompella, Uday B: 3 articles (12/2009 - 06/2009)
2.	Sundaram, Sneha: 3 articles (12/2009 - 06/2009)
3.	Fontaine, Christelle: 2 articles (12/2020 - 10/2020)
4.	Niżański, Wojciech: 2 articles (12/2020 - 10/2020)
5.	Ochota, Małgorzata: 2 articles (12/2020 - 10/2020)
6.	Pasikowska, Joanna: 2 articles (12/2020 - 10/2020)
7.	Milani, C: 2 articles (12/2012 - 07/2009)
8.	Mollo, A: 2 articles (12/2012 - 07/2009)
9.	Romagnoli, S: 2 articles (12/2012 - 07/2009)
10.	Stelletta, C: 2 articles (12/2012 - 07/2009)

Related Diseases

1.	Infertility (Sterility) 12/01/2012 - "Our results (i) confirm the efficacy of deslorelin in causing reversible sterility in male dogs, (ii) confirm and provide details about endocrine and seminal parameters involved in this process and (iii) contribute to define the interval between treatment and achievement of complete sterility. " 01/22/2023 - "The deslorelin implant Suprelorin® 4.7 mg (Virbac, Carros, France) is a safe and effective neutering option, inducing infertility over a 12-month period when administered to intact male cats aged between 3 months of age and 11 years of age. " 01/01/2017 - "The purpose of this study was to investigate semen quality and interval to sterility in tom cats treated with a 9.4 mg deslorelin implant. " 12/01/2012 - "The purpose of this study was to define (i) the interval between treatment and sterility, and (ii) semen quality in male dogs administered a 4.7-mg deslorelin implant. " 01/12/2023 - "Deslorelin is currently registered for the induction of temporary infertility in male dogs, male cats, male ferrets, and also prepubertal female dogs, but research has shown its usefulness for other conditions requiring chronic treatment. "
2.	Prostatic Neoplasms (Prostate Cancer) 06/01/2009 - "Cell cycle analysis showed that docetaxel treatment led to arrest in G(2)-M phase, whereas deslorelin-docetaxel treatment allowed greater progression to apoptosis in both cell lines, with deslorelin-docetaxel exerting 5-fold greater apoptosis compared with docetaxel in prostate cancer cell lines. " 06/01/2009 - "Thus, deslorelin-docetaxel prepared in this study retains pharmacologic effects of both docetaxel and deslorelin while enhancing the antiproliferative, apoptotic, and antitumor efficacy of docetaxel by several folds in prostate cancer therapy." 06/01/2009 - "Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy."
3.	Edema (Dropsy) 06/01/2022 - "In conclusion, cycling mares displayed a highly efficacious response to deslorelin acetate and apparently normal luteal function during the fall, despite lower edema scores in late fall." 06/01/2015 - "Ovulations were induced with 1 mg (intramuscular) of deslorelin acetate after the observation of a greater than 35 mm follicle and uterine edema. "
4.	Pruritus (Itching) 05/01/2005 - "Compared with findings before deslorelin treatment, vulvar swelling, pruritus, sexual behaviors, and aggression were significantly decreased or eliminated within 14 days of implantation; hair regrowth was evident 4 to 6 weeks after treatment. "
5.	Lung Neoplasms (Lung Cancer) 12/01/2009 - "To evaluate the efficacy of a novel docetaxel derivative of deslorelin, a luteinizing hormone-releasing hormone (LHRH) agonist, and its combination in vivo with RGD peptide conjugated nanoparticles encapsulating an antiangiogenic, anti-vascular endothelial growth factor (VEGF) intraceptor (Flt23k; RGD-Flt23k-NP) in H1299 lung cancer cells and/or xenografts in athymic nude BALB/c mice. "

Related Drugs and Biologics

1.	Docetaxel (Taxotere)
2.	Gonadotropin-Releasing Hormone (GnRH)
3.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
4.	LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)
5.	arginyl-glycyl-aspartic acid
6.	Progesterone
7.	Estradiol (Delestrogen)
8.	Hormones (Hormone)
9.	Testosterone (Sustanon)
10.	Leuprolide (Lupron)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Contraception (Birth Control)
4.	Castration
5.	Palliative Care (Palliative Therapy)